Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin Submits Once-Weekly Byetta After Shedding 200 Sales Reps

This article was originally published in The Pink Sheet Daily

Executive Summary

Label with expanded language about thyroid cancer risk is expected.

You may also be interested in...



Byetta Needs More Studies To Determine Pancreatitis Risks, FDA Says

The previously undisclosed requirements are a setback to Amylin and Lilly, which jointly market the drug and plan a once-weekly version.

Byetta Needs More Studies To Determine Pancreatitis Risks, FDA Says

The previously undisclosed requirements are a setback to Amylin and Lilly, which jointly market the drug and plan a once-weekly version.

FDA's Handling Of Byetta Pancreatitis Risk Could Bode Well For Other Diabetes Drugs

Amylin's Byetta cleared for first-line use without a black box stigma, but sales may still not get a lift.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel